NCT00602394已完成不适用
A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fed conditions using a single-dose, randomized, 2 treatment, 2-period, 2-sequence crossover design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 38 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs.
- •History of allergic or adverse response to lithium, or any comparable or similar product.
结局指标
主要结局
Bioequivalence
时间窗: Baseline, Two period, Fourteen day washout
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting ConditionsBipolar DisorderNCT00601536Roxane Laboratories29
已完成
不适用
Bioequivalency Study of 450 mg Lithium Carbonate Under Fed ConditionsBipolar DisorderNCT00601575Roxane Laboratories30
已完成
不适用
Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting ConditionsBipolar DisorderNCT00602381Roxane Laboratories30
已完成
不适用
Bioequivalency Study of Calcitriol Tablets Under Fasting ConditionsSecondary HyperparathyroidismHypocalcemiaNCT00601328Roxane Laboratories36
已完成
不适用
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed ConditionsRestless Leg SyndromeParkinson's DiseaseNCT00674310Roxane Laboratories29